Afghanistan's Hidden Drug Problem

Total Page:16

File Type:pdf, Size:1020Kb

Afghanistan's Hidden Drug Problem AFGHANISTAN RESEARCH AND EVALUATION UNIT Briefi ng Paper Series David Macdonald October 2008 Afghanistan’s Hidden Drug Problem: The Misuse of Psychotropics Overview Contents Over the past decade, Afghanistan has gained notoriety as the world’s I. Background 3 leading producer of opium and heroin. What is less well known is that, II. The Regulatory according to available evidence, the Environment and country itself also has an increasing Supply of number of problem drug users.1 Psychotropics 6 Apart from dependency, addiction and other health-related problems, III. The Misuse of problem drug use can lead to a wide Psychotropics range of social, economic and legal in Afghanistan 10 problems that affect individuals, Commonly misused psychotropics families and communities. It is not IV. Policy Implications 15 only the use of illicit substances that leads to problem drug use. It also results from the use of psychotropics — pharmaceutical drugs like V. Ways Forward 16 painkillers and tranquillisers that have a psychoactive effect — in ways not recommended by a qualifi ed doctor or the manufacturer. Glossary of Psychotropics While popular perceptions of drug misuse and dependency in Used in Afghanistan 18 Afghanistan tend to focus on illicit drugs like opium or heroin and to a lesser extent cannabis, evidence suggests that many people also misuse psychotropics. A national survey conducted in 2005 by the United Nations Offi ce on Drugs and Crime (UNODC) and the Ministry of Counter Narcotics looked at the incidence of the non-medical About the Author use of controlled substances, including use without a doctor’s prescription, for an excessive or unjustifi ed period of time. While David Macdonald is a the estimated numbers of opium users and heroin users were 150,000 sociologist with over 20 and 50,000 respectively, the number of problem pharmaceutical years’ experience working on drug demand reduction issues in the developing 1 world. He has worked as a The information in this paper comes from interviews with pharmacists, government offi cials, drug treatment workers, doctors and drug users, as well demand reduction specialist as from other research reports and anecdotal accounts. All numerical estimates for UNODC’s Afghanistan of drug supply and use in Afghanistan should be treated with caution: while they programme and as an indicate general trends and patterns and may inform policymaking, they are advisor to the Ministries estimates only and cannot be considered as confi rmed numbers. Estimates of of Counter Narcotics and drug use and misuse are notoriously diffi cult to calculate, and globally there is a Public Health in Kabul. dearth of reliable information about the magnitude and nature of drug problems. David Macdonald, Drugs in Afghanistan: Opium, Outlaws and Scorpion Tales (London: Pluto Press, 2007), 16-36. 1 Afghanistan Research and Evaluation Unit drug users was estimated to be 180,000.2 In Acronyms 2003, an assessment of problem drug use in AIDS acquired immunodefi ciency Kabul city found 14,298 users of pharmaceutical syndrome drugs compared to 10,774 opium users and 7,008 heroin users.3 EC European Commission HIV human immunodefi ciency There is a range of types of psychotropic drug virus misuse in Afghanistan. One problem in particular is the long-term self-medication without a IDU injecting drug user doctor’s prescription using powerful painkillers INCB International Narcotics and tranquillisers such as diazepam (brand name Control Board Valium), which is cheap and widely available from LSD lysergic acid diethylamide pharmacies and other retail outlets. NGO non-governmental While there may be many reasons for such misuse, organisation confl ict-related poverty, social displacement SSRIs selective serotonin and mental health problems (including chronic reuptake inhibitors anxiety, depression and post-traumatic stress disorder) are known to have been central drivers UN United Nations of this problem. UNHCR United Nations High Commissioner for Refugees Psychotropics are known to be increasingly taken in combination with illicit drugs such as opium UNICEF United Nations and heroin, either through smoking or injection. Children’s Fund Overprescribing of psychotropics by doctors UNIFEM United Nations Development and the lack of reliable information about the Fund for Women associated risks and dangers — including possible UNODC United Nations Offi ce on side effects, intoxication and dependency — also Drugs and Crime contribute to misuse. For example, it has been reported that very young children are given UNDCP United Nations International inappropriate drugs such as psychotropic-based Drug Control Programme cough syrups or powerful painkillers. WHO World Health Organization However, the misuse of psychotropics is not a problem limited to Afghanistan. Other developing Psychotropic drugs are pharmaceutical drugs countries, and indeed several developed ones, such as painkillers and tranquillisers that have also experience similar diffi culties in controlling a psychoactive effect. They make up part of and regulating the supply (by prescription and the category of psychoactive drugs, which are sale from a registered qualifi ed pharmacist) mind-altering substances affecting the central and use (under the supervision of a doctor) of nervous system that can lead to a variety of psychotropics for medical reasons. changes in behaviour, mood and perception. In Afghanistan it is estimated that up to 80 percent of the psychotropics available have been The UK’s Advisory Council on the Misuse of smuggled into the country without a licence and Drugs defi nes a problem drug user of either without testing to determine whether they contain licit or illicit substances as: additives or are counterfeit or out of date. While border controls are weak, so are the control and any person who experiences social, regulation of psychotropics within the country psychological, physical or legal problems itself. The Ministry of Public Health recently related to intoxication and/or the regular established a legal department in its Directorate of excessive consumption and/or dependence 2 as a consequence of his own use of drugs UNODC and Ministry of Counter Narcotics, Afghanistan: Drug Use Survey 2005 (Kabul: UNODC Country Offi ce for or other chemical substances. Afghanistan, 2005). Advisory Council on the Misuse of Drugs, “Treatment and 3 UNODC, Community Drug Profi le No. 5: An Assessment Rehabilitation” (London: HMSO, 1982) of Problem Drug Use in Kabul City (Kabul: UNODC Afghanistan Programme, 2003). 2 Afghanistan’s Hidden Drug Problem: The Misuse of Psychotropics Pharmacy to control and monitor pharmacies and any reduction in the availability or increase in the medical institutions and to check whether out-of- price of heroin is likely to lead to increased use date, expired or low-quality medicines are being of a range of psychotropics as substitute drugs, sold. But with over 9,000 registered pharmacies potentially encouraging a burgeoning illicit street that need constant checking by low-paid, under- market in these substances. resourced government offi cials susceptible to bribes and other forms of corruption, this The problems facing Afghanistan in relation to represents a challenge. There is a clear need for the misuse of both licit and illicit drugs, including stricter regulation of the sale and distribution of psychotropics, cannot be solved overnight. They psychotropics from other retail outlets, such as require a long-term strategy and commitment by shops and handcarts in marketplaces, as well as the government and the international community of their “prescription” and purchase from people to tackle them. Even if opium was eradicated, the with no medical qualifi cations or expertise. country would still have a demand-driven drug problem — with psychotropics at its core. While The supply of and demand for psychotropics are strengthening government institutions to be able inextricably linked to the trade in illicit drugs like to control and regulate the supply and distribution opium, heroin and cannabis. Any steep rise in the cost of psychotropics is necessary, the following are of psychotropics coupled with a decrease in their also essential: better resourced treatment, availability and ease of access may lead problem rehabilitation and harm reduction services for users to substitute pharmaceutical psychotropics problem drug users; training for doctors and with drugs like opium and hashish — both of which pharmacists on the risks and dangers of psychotropic have a long history of social and medical use in drug misuse; and provision of reliable and context- Afghanistan. Current heroin users are increasingly sensitive information for the Afghan public about combining heroin with psychotropic drugs, and the costs and benefi ts of psychotropic drugs. I. Background The global policy framework By 1971, it was recognised that many psychoactive drugs had not been included in the 1961 Convention, In 1961, the United Nations Single Convention leading to the drafting of the UN Convention on on Narcotic Drugs was developed to prohibit the Psychotropic Substances.4 The 1971 Convention production and supply of narcotic drugs and drugs was primarily concerned with the scheduling with similar effects, specifi cally cannabis, coca and control of a wide range of drugs classifi ed and opium and their derivatives such as hashish, as psychotropics from pharmaceutical drugs like cocaine, morphine and heroin — except for the amphetamine-type stimulants, barbiturates and purposes
Recommended publications
  • A Policy Perspective on the Global Use of Smokeless Tobacco
    Curr Addict Rep DOI 10.1007/s40429-017-0166-7 TOBACCO (AH WEINBERGER, SECTION EDITOR) A Policy Perspective on the Global Use of Smokeless Tobacco Kamran Siddiqi1 & Aishwarya Lakshmi Vidyasagaran1 & Anne Readshaw1 & Ray Croucher2 # The Author(s) 2017. This article is an open access publication Abstract Keywords Smokeless tobacco . Snus . Tobacco control . Background Globally, over 300 million people consume di- Global health verse smokeless tobacco (ST) products. They are addictive, cause cancer, increased cardiovascular mortality risks and poor pregnancy outcomes. Introduction Purpose of Review To identify gaps in implementing key ST demand-reduction measures, focused literature reviews were “Smokeless tobacco” (ST) comprises tobacco products that do conducted and findings synthesized according to relevant not involve a combustion process, such as chewing, nasal and WHO Framework Convention on Tobacco Control (FCTC) oral tobacco [1•]. Globally, over 300 million people consume Articles. ST [1•], yet ST has been largely neglected in research and Recent Findings The literature supports implementation of policy arenas because it is generally regarded as less harmful ST demand-reduction measures. For taxation, labelling and than cigarettes. It is also seen as a regional rather than a global packaging, most administrations have weaker policies for ST problem, and too diverse and complex to control. than cigarettes. Capacity to regulate ST contents and offer ST use is reported in at least 116 countries worldwide, cessation support is lacking. There is poor compliance with including countries in Africa, Asia, Europe and the bans on ST advertising, promotion and sponsorship. Americas [2•]. Smokeless tobacco consumption is therefore Summary The literature on implementation of WHO a global public health issue.
    [Show full text]
  • 2020 International Narcotics Control Strategy Report
    United States Department of State Bureau for International Narcotics and Law Enforcement Affairs International Narcotics Control Strategy Report Volume I Drug and Chemical Control March 2020 INCSR 2020 Volume 1 Table of Contents Table of Contents Common Abbreviations ..................................................................................................................................... iii International Agreements.................................................................................................................................... v INTRODUCTION ..................................................................................................................................... 1 Legislative Basis for the INCSR ......................................................................................................................... 2 Presidential Determination ................................................................................................................................. 7 Policy and Program Developments .................................................................................................... 12 Overview ......................................................................................................................................................... 13 Methodology for U.S. Government Estimates of Illegal Drug Production .......................................................... 18 Parties to UN Conventions ..............................................................................................................................
    [Show full text]
  • Finland Country Drug Report 2017
    Finland Country Drug Report 2017 Contents: At a glance | National drug strategy and coordination (p. 2) | Public expenditure (p. 3) | Drug laws and drug law offences (p. 4) | Drug use (p. 5) | Drug harms (p. 8) | Prevention (p. 10) | Harm reduction (p. 11) | Treatment (p. 12) | Drug use and responses in prison (p. 14) | Quality assurance (p. 15) | Drug-related research (p. 15) | Drug markets (p. 16) | Key drug statistics for Finland (p. 18) | EU Dashboard (p. 20) THE DRUG PROBLEM IN FINLAND AT A GLANCE Drug use Treatment entrants Overdose deaths Drug law offences in young adults (15-34 years) by primary drug in the last year 250 Cannabis 200 23 478 166 150 13.5 % Top 5 drugs seized 100 ranked according to quantities Cannabis, 21% 50 measured in kilograms Amphetamines, 15 % Cocaine, 0 % 0 1. Amphetamine 2011 2012 2013 2015 2014 Opioids, 52 % 2010 2007 2008 2006 9 % 17.9 % 2009 Other, 12 % 2. Herbal cannabis Other drugs Opioid substitution HIV diagnoses 3. Cannabis resin MDMA 2.5 % treatment clients attributed to injecting 4. Cocaine Amphetamines 2.4 % 14 5. Heroin Cocaine 1 % 12 3 000 10 Population 8 (15-64 years) 6 7 High-risk opioid users Syringes distributeddistributed 4 through specialised 2 3 483 757 programmes 0 13 836 2011 2012 2013 2015 2014 2010 2007 2008 2006 2009 Source: EUROSTAT (12 700 - 15 090) 5 301 000 Source: ECDC Extracted on: 26/03/2017 NB: Data presented here are either national estimates (prevalence of use, opioid drug users) or reported numbers through the EMCDDA indicators (treatment clients, syringes, deaths and HIV diagnosis, drug law offences and seizures).
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Framework Convention on Tobacco Control (WHO FCTC) Is the First Treaty Negotiated Under the Auspices of the World Health Organization
    World Health Organization Geneva, Switzerland WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL World Health Organization WHO Library Cataloguing-in-Publication Data WHO Framework Convention on Tobacco Control. 1.Tobacco - supply and distribution 2.Tobacco industry - legislation 3.Tobacco smoke pollution - prevention and control 4.Tobacco use cessation 5.Treaties I.World Health Organization. ISBN 92 4 159101 3 (LC/NLM classification: HD 9130.6) © World Health Organization 2003, updated reprint 2004, 2005 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • COVID and Beyond Dart RC Opioid Abuse
    Trends within Drug Abuse and Healthcare – COVID and Beyond Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Safety, Denver Health Executive Director, RADARS® System Professor, University of Colorado School of Medicine Competing Interests RADARS® System is the property of The Denver Health and Hospital Authority (DHHA), a political subdivision of the State of Colorado. RADARS® System is supported by subscriptions from pharmaceutical manufacturers, government and nongovernment agencies for surveillance, research, and reporting services. No subscriber participated in the conception, analysis, drafting, or review of this presentation. 2 3 What Caused the US Opioid Crisis - HHS • In the late 1990s, pharmaceutical companies reassured the medical community that patients would not become addicted to opioid pain relievers and health care providers began to prescribe them at greater rates. • Increased prescription of opioid medications led to widespread misuse of both prescription and non-prescription opioids before it came clear that these medications could indeed be highly addictive. • 2017 HHS declared a public health emergency and announced a five point strategy to combat the opioid crisis https://www.hhs.gov/opioids/about-the-epidemic/index.html 4 What Really Happened? • Health care systems and regulation • Fifth vital sign, patient “satisfaction,” etc. • Careless doctors • We knew better, but let convenience win out. • Criminal behavior • Opioid marketing • Aggressive, irresponsible • Increased supply of illicit opioids • Lack of treatment for OUD • Good, but after the fact, insufficient to meet demand • Increased demand? 5 What Happened to Rx Drug Abuse? 10 Years ago… Prescription drug abuse is the Nation's fastest-growing drug problem, and the Centers for Disease Control and Prevention has classified prescription drug abuse as an epidemic.
    [Show full text]
  • Civil Society Monitoring of Harm Reduction in Europe, 2019
    Correlation Correlation European DATA REPORT Eropean Harm Reduction R C Network C Network CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 DATA REPORT 1 CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 ® Correlation – European Harm Reduction Network, 2019. This publication of Correlation – European Harm Reduction Network is protected by copyright. Reproduction is authorised provided the source is acknowledged. Recommended citation: Tammi, T., Rigoni, R., Matičič, M., Schäffer, D., van der Gouwe, D., Schiffer, K., Perez Gayo, R., Schatz, E. (2020): Civil Society Monitoring of Harm Reduction in Europe, 2019. Data Report. Correlation European Harm Reduction Network, Amsterdam. Correlation – European Harm Reduction Network c/o Foundation De REGENBOOG GROEP Droogbak 1d 1013 GE Amsterdam The Netherlands www.correlation-net.org This project has been supported by the European Commission. Correlation - European Harm Reduction Network is co-funded by the European Union 2 Correlation European DATA REPORT Harm Reduction C Network CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 DATA REPORT 3 CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 CONTRIBUTORS Editor: The data network: Graham Shaw Albania: Genci Mucollari, Aksion Plus Austria: Alexandra Karden & Barbara Siokola, Scientific expert group: Suchthilfe Wien Tuukka Tammi (THL), Dagmar Hedrich (EMCDDA), Belgium: Peter Blanckaert & Tessa Windelinckx, Sam Shirley-Beavan (HRI), Perrine Roux (INSERM). Free Clinic Bosnia and Herzegovina: Samir Ibisevic, PROI
    [Show full text]
  • Dieses Dokument Ist Eine Zweitveröffentlichung (Verlagsversion) / This Is a Self-Archiving Document (Published Version)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Technische Universität Dresden: Qucosa Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / This is a self-archiving document (published version): Jan Gaertner, Ulrike M. Stamer, Constanze Remi, Raymond Voltz, Claudia Bausewein, Rainer Sabatowski, Stefan Wirz, Gabriele Müller-Mundt, Steffen T. Simon, Anne Pralong, Friedemann Nauck, Markus Follmann, Lukas Radbruch, Winfried Meißner Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice Erstveröffentlichung in / First published in: Palliative Medicine. 2017, 31(1), S. 26 – 34 [Zugriff am: 19.08.2019]. SAGE journals. ISSN 1477- 030X. DOI: https://doi.org/10.1177/0269216316655746 Diese Version ist verfügbar / This version is available on: https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-353637 „Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. Nationallizenz frei zugänglich.“ This publication is openly accessible with the permission of the copyright owner. The permission is granted within a nationwide license, supported by the German Research Foundation (abbr. in German DFG). www.nationallizenzen.de/ 6557467464 PMJ0010.1177/0269216316655746Palliative10.110.1177/0269216316655746177/0269216316655746Palliative MedicineGaertner et al. research-article2016 Review Article Palliative Medicine 2017, Vol. 31(1) 26 –34 Metamizole/dipyrone for the relief © The Author(s) 2016
    [Show full text]
  • The Impact of Drug Policy on Women
    THE IMPACT OF DRUG POLICY ON WOMEN Kasia Malinowska-Sempruch & Olga Rychkova As member states of the United Nations take stock of the 02 INTRODUCTION drug control system, a number of debates have emerged among governments about how to balance international 03 WHAT THE UN AND OTHER INTERNATIONAL BODIES SAY drug laws with human rights, public health, alternatives to incarceration, and experimentation with regulation. 07 ISSUES RELEVANT TO UNGASS DEBATES This series intends to provide a primer on why governments 18 CONCLUSIONS AND RECOMMENDATIONS must not turn a blind eye to pressing human rights and public health impacts of current drug policies. 01 THE IMPACT OF DRUG POLICY ON WOMEN WHAT IS THE IMPACT OF DRUG POLICY ON WOMEN? “Who ever heard of a female drug lord? As the terms ‘kingpin’ and ‘drug lord’ denote, men are almost always at the head of major drug operations, and yet the rate of imprisonment of women for drug crimes has far outpaced that of men. Families and children suffer—but why?” –American Civil Liberties Union et al., Caught in the Net, 2005 1 1 American Civil Liberties Union (ACLU), Breaking the Chains and Brennan Center for Justice. Caught in the net: the impact of drug policies on women and families. New York, 2005. At: https://www.aclu.org/drug-law-reform/caught-net-impact-drug-policies-women-and-families. 02 THE IMPACT OF DRUG POLICY ON WOMEN INTRODUCTION In the public mind, the “war on drugs” probably conjures up a male image. In most countries, official statistics would show that men, indeed, are the majority of people who use drugs recreationally, who have problematic use, and who sell drugs.
    [Show full text]
  • Clinical Study Protocol
    CLINICAL STUDY PROTOCOL COmparison of the effect of treatment with NSAIDs added to anti- TNF therapy versus anti-TNF therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis: a randomized controlled multicentre trial (CONSUL) Protocol number: CONSUL2016 Protocol version: 1.3 including Amendment No. 1 Date: 13.02.2017 EudraCT Number: 2016‐000615‐33 Investigational Products: Golimumab, Celecoxib Study Phase: phase IV Study Design: randomized, controlled, prospective, open-label, multicentrestudy Sponsor: Charité Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin, Germany Coordinating Investigator: Prof. Dr. med. Denis Poddubnyy Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie Campus Benjamin Franklin Charité Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin, Germany Tel: +49 30 8445-2302 or 450-514544 Fax: +49 30 8445-4149 Email: [email protected] Study Physician: Dr. med. Burkhard Muche -same address- Tel. +49 (30) 8445-4144 Email: [email protected] 4. CONSUL_Protocol_Version_1.3_with_Amendment_1_13.02.2017_clear.docx Page 1 of 61 TABLE OF CONTENT 1 LIST OF ABBREVIATIONS ................................................................................................. 4 2 PROTOCOL SYNOPSIS ..................................................................................................... 6 3 ASSESSMENT SCHEDULE .............................................................................................. 13 4 INTRODUCTION
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • Summary of Synthetic Opioid Testing Within the Department of Defense
    SUMMARY OF SYNTHETIC OPIOID TESTING WITHIN THE DEPARTMENT OF DEFENSE Tom Martin, Ph.D. Liaison to Director, DoD Drug Testing and Program Policy PERSONNEL AND READINESS PERSONNEL AND READINESS Drug Demand Reduction Program Mission and Scope Mission: Enable operational readiness, safety, and security of the Total Force by deterring illicit and prescription drug abuse through robust and dynamic drug testing; emerging drug threat surveillance; prevention, education, and outreach efforts; and development of new testing procedures. Scope: All DoD components and DoD civilians in testing designated positions (TDPs) Policies: DODI 1010.01 “Military Personnel Drug Abuse Testing Program (MPDATP)” DODI 1010.09 “DoD Civilian Employee Drug-Free Workplace Program” DODI 1010.16 “Technical Procedures for the Military Personnel Drug Abuse Testing Program (MPDATP)” PERSONNEL AND READINESS DDRP Driving Factors • Drug abuse in the general U.S. 18-25 year old male group is estimated to be 17-20%– the population from which the Service recruits their enlisted personnel • Before DoD instituted drug testing among Service personnel, drug use was a significant recurring problem – Vietnam (estimated over 5% of returning service members addicted to heroin) – 1981 CVN Nimitz aviation mishap – 14 killed, 48 injured, 7 aircraft destroyed, 11 aircraft damaged, $150M in damages, six deceased with detectable levels of marijuana • Notable increase in abuse/misuse of prescription pain medications • Personnel abusing illicit drugs or prescription medications are a safety hazard
    [Show full text]